A brief review of drug discovery research for Human African Trypanosomiasis
Human African Trypanosomiasis (HAT), a neglected disease endemic in Sub-Saharan Africa, is usually fatal if left untreated. It is caused by the parasite Trypanosoma brucei, and is spread by the tsetse fly. The drugs currently available to treat HAT are few, and limited in efficacy. Furthermore, resi...
| Main Authors: | , |
|---|---|
| Format: | Journal Article |
| Published: |
Bentham Science Publishers
2017
|
| Online Access: | http://hdl.handle.net/20.500.11937/51570 |
| _version_ | 1848758730393387008 |
|---|---|
| author | Cullen, Danica Mocerino, Mauro |
| author_facet | Cullen, Danica Mocerino, Mauro |
| author_sort | Cullen, Danica |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | Human African Trypanosomiasis (HAT), a neglected disease endemic in Sub-Saharan Africa, is usually fatal if left untreated. It is caused by the parasite Trypanosoma brucei, and is spread by the tsetse fly. The drugs currently available to treat HAT are few, and limited in efficacy. Furthermore, resistance towards these drugs is beginning to grow. In the last 25 years only one advance has been made into HAT treatment and consequently, there is an increasing need for new drugs to be sought that are able to effectively treat this disease. This review provides a brief overview of drug discovery research for HAT, focusing on research published in the last four years, identifying new molecules with the potential to be developed into anti-HAT agents. The methods of drug discovery have been grouped into three key areas; new molecules inspired by known antitrypanosomal agents, target-based screening, and phenotypic screening. |
| first_indexed | 2025-11-14T09:48:38Z |
| format | Journal Article |
| id | curtin-20.500.11937-51570 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T09:48:38Z |
| publishDate | 2017 |
| publisher | Bentham Science Publishers |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-515702017-09-13T21:24:49Z A brief review of drug discovery research for Human African Trypanosomiasis Cullen, Danica Mocerino, Mauro Human African Trypanosomiasis (HAT), a neglected disease endemic in Sub-Saharan Africa, is usually fatal if left untreated. It is caused by the parasite Trypanosoma brucei, and is spread by the tsetse fly. The drugs currently available to treat HAT are few, and limited in efficacy. Furthermore, resistance towards these drugs is beginning to grow. In the last 25 years only one advance has been made into HAT treatment and consequently, there is an increasing need for new drugs to be sought that are able to effectively treat this disease. This review provides a brief overview of drug discovery research for HAT, focusing on research published in the last four years, identifying new molecules with the potential to be developed into anti-HAT agents. The methods of drug discovery have been grouped into three key areas; new molecules inspired by known antitrypanosomal agents, target-based screening, and phenotypic screening. 2017 Journal Article http://hdl.handle.net/20.500.11937/51570 10.2174/0929867324666170120160034 Bentham Science Publishers restricted |
| spellingShingle | Cullen, Danica Mocerino, Mauro A brief review of drug discovery research for Human African Trypanosomiasis |
| title | A brief review of drug discovery research for Human African Trypanosomiasis |
| title_full | A brief review of drug discovery research for Human African Trypanosomiasis |
| title_fullStr | A brief review of drug discovery research for Human African Trypanosomiasis |
| title_full_unstemmed | A brief review of drug discovery research for Human African Trypanosomiasis |
| title_short | A brief review of drug discovery research for Human African Trypanosomiasis |
| title_sort | brief review of drug discovery research for human african trypanosomiasis |
| url | http://hdl.handle.net/20.500.11937/51570 |